
FE SUNDAY

Achievers Media

NAC

Bandra (W.), Phone: 22691584

Mobile: 9664132358



Phone: 28645005

Borivali (E) Phone: 42872727

Mobile: 9833364551/ 9820199918

P. V. Advertisers.

Jogeshwari (W)

Mobile: 9820123000

Mobile: 9820433200

27898472

Siba Ads & Communications,

Phone: 27892555/ 61372555

Mobile: 9820889848

आन्ध्रा बैंक Andhra Bank **BRANCH: WAGHOLI**

GATE NO 1420 SAHAYADRI WAREHOUSING COMPLEX NEAR WAGHESWARA TEMPLE NAGAR ROAD, PUNE MH-412207 Tel No.020-27052734

NOTICE OF E-AUCTION

(Rule 9 of Security Interest (Enforcement) Rules, 2002)

WHEREAS, the following borrower mentioned below have availed credit facilities from Andhra Bank, Wagholi branch and have defaulted to pay and is due to the Bank Amount i costs and charges. Therefore Andhra Bank in exercise of Powers conferred U/S 13 of The Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act 54 of 2002 has decided to sell the property detailed below in Public auction to be conducted on 20-03-2020 by the way of e-auction through website/portal detailed hereunder. The reserve price of the secured Asset detailed hereafter is fixed at column No. 6 below which the property

The persons interested in participating in the e-auction and purchasing the property shall deposit EMD mentioned in column No. 7 (10% of the reserve price) towards earnest money by way of EFT/RTGS/NEFT transfer in favour of the Authorized Officer, Andhra Bank Wagholi branch to the credit of the A/c No. 17461029380121 Andhra Bank, Wagholi, the Branch Code being 1746, IFSC Code ANDB0001746. The EMD has to be deposited on or before The intending purchasers after payment of the EMD have to register their name with the e-auction service provider given below and obtain their user id and password. The intending purchasers can take the assistance of the service

provider in creation of Login ID & Password, uploading data, submitting bid and can also get training on e-auction free of cost. The intending purchaser holding a valid user ID/ Password and confirmed payment of EMD through NEFT. RTGS shall alone be eligible for participating in the e-Auction process subject to clearance by the Authorized Officer. Minimum Bid multiples shall be as mentioned in column No.8. The property will be e-auctioned on 20-03-2020 on the website of https://antaressystems.com (e-auction service provider) between 11 a.m to 1 p.m with auto time extension of 5 minutes each, till the sale is concluded/closed. The property would be sold to the bidder who offers highest price/ bid, and the sale shall be subject to confirmation by the Bank. The successful bidder/purchaser will have to deposit the 25% of the price/bid amount inclusive of earnest money deposited immediately i.e., on the same day or not later than the next working day, as the case may be with the Authorized Officer and in default of such deposit, the property shall be sold again. The balance 75% of the amount shall have to be deposited by the purchaser on or before the 15th day of confirmation of Sale of the immovable property

or such extended period as may be agreed upon in writing between the purchaser and secured creditor. If the amount is not paid within the stipulated time, the amount deposited shall be forfeited and the bank will be at liberty to sell the property again. There are no encumbrances known to the Bank on the Property. The parties interested to inspect the property may contact the Branch on week days between 10 AM and 4 PM. The parties participating in the auction should carry out proper due diligence over the property before participating in the auction. Bank shall not be responsible in any way at a later date for any dispute regarding the property on any count. As per Section 194-IA of the Income Tax Act 1961, TDS @ 1% will be applicable on the sale proceeds where the sale consideration is Rs. 50,00,000 (Rupees Fifty Lakhs) and above. The successful bidder/purchaser shall deduct

1% TDS from the Sale Price and deposit the same with the Income Tax department in Form No. 16-B, containing the Bank's name and the Pan No. AABCA7375C as a seller and submit the original receipt of the TDS Certificate to the Bank. The purchaser shall be liable for payment of local taxes, Excise duty and any other statutory dues. The Registration charges and stamp duty on the documents executed for affecting the sale shall be borne by the purchaser. The property will be sold as per the Terms and Conditions displayed on the website of the service provider on as is where is and as is what is basis. The intending bidders should make discrete enquiry as regards any claim, charges, encumbrances on the properties of any authority, besides the Banks charges and should satisfy themselves about the title, extent, quality and quantity of the property before submitting their bid. No claim of whatsoever nature regarding the property put for sale, charges/ encumbrances over the property or on any matter etc will be entertained after submission of the online bid. The decision of the bank regarding sale of the property shall be final, binding and will not be open to question. The Authorized Officer reserves the right to cancel or postpone the sale without assigning any reasons.

Details of Borrower(s)/ Guarantor(s)/ Mortgagor(s) & Property (Immovable & Movables) etc.

Sr.		Name & Address of the Mortgagor(s)	Description of Properties	Amount Due as	Reserve Price (in	EMD Amount	Minimum Bid
No				on 31/01/2020	Rs.) of the land	(10% of	Increment by Which
	Borrower(s)				buliding, plant &	Reserve Price)	the Bid Amount is
					machinery	(in Rs.)	to be Increased (In
							Rs.)
	2	3	4	5	6	7	8
	M/s Balesha	1.Mr. Rohidas Harishchandra Bhosale	1. Land and Building:- Residential land & building belonging	Rs. 4,69,26,212/-	Rs.3,00,00,000/-	Rs. 30,00,000/-	Rs. 1,00,000/-
	Milk and Milk	(Guarantor and Mortgager 1) Address:-	to Mr Rohidas Harishchandra Bhosale (Guarantor & Mortgager	(Rupees Four	(Rupees Three	(Rupees	(Rupees One
	Products Pvt	Gat No 474/1, Situated at Village Mauje)& Commercial Land & building belonging to M/S Balesha Milk	Crore	Crores Only)	Thirty Lakhs	Lakh Only)
	Ltd. (Directors:	Nirvi, Tal Shirur, Dist, Pune 412210	& Milk products Pvt Ltd (Borrower & Mortgagor) along with Plant	Sixty Nine Lakhs		only)	Lakii Oliiy)
	Mr Rohidas	2.Mrs. Sunita Rohidas Bhosale	& machinery situated at Gat no 474/1, Village Nirvi, Tal Shirur,	Twenty Six		(1.1.5)	
	Harichandra	(Guarantor 2) Address:- Gat No 474/1,	pune 412210 and bounded by : East : By Part of Gat no 474 West:	Thousand Two			
	Bhosale & Mrs	Situated at Village Mauje Nirvi, Tal	By Shirur to siddhatek road North : By Internal road, South : By	Hundred			
11	Sunita Rohidas	Shirur, Dist, Pune 412210	N.A land of Mr Rohidas Bhosale	Twelve only)			
	Bhosale),	3.Mrs. Manda Prakash Patole	2. Land and Building:- Residential belonging to Manda Prakash	• /	Rs. 47,60,000/-	Rs. 4,76,000/-	Rs. 1,00,000/-
11	Address: Gat	(Guarantor and Mortgager	Patole (Guarantor) situated at Land and Bungalow Unit At Hissa No.		(Rupees Forty	(Rupees Four	(Rupees One
11	No 474/1,	3)Address:- Gat No. 1494, Vastu	04 (P) (Ground Floor), On North Side of GAT No 1088 (OLD GAT No		seven lakhs sixty	lakh seventy	Lakh Only)
	· ·	No 909/99, Kesanand Road,	1594), Mauje Wagholi, Taluka Haveli, Dist. Pune- 412207 and bounded		Thousand only)	six Thousand	.,
	Situated at	Kalewada, NR. Sanskruti Mangal	by:East : By Road, West: By Old GAT No 1590/1595/1596,North : By		'	only)	
	Village Mauje	Karyalaya, Wagholi, Pune- 412207	Hissa No 03, South : By Part of Hissa No 04				
	Nirvi, Tal Shirur,	4.Mr. Mansingh Laxmanrao Sonavane	3. Land and Building:- Residential belonging to Mansing		Rs. 35,10,000/-	Rs. 3,51,000/-	Rs. 50,000/-
	Dist, Pune	(Guarantor and mortgager 4)Address:	Laxmanrao Sonawane (Guarantor), situated at NA Land bearing		(Rupees Thirty	(Rupees Three	(Rupees Fifty
11	412210	NA Land Bearing Plot No 14, Gurukul	Plot No 14, Gurukul HSG Society, SR No. 52/1/2, Tal Shirur, Dist		five	lakhs fifty one	Thousand only)
		HSG Society, SR No. 52/1/2, Tal Shirur,	Pune- 412210 and bounded by: East: Plot No 15, West: Part of		lakhs ten	Thousand only)	
		Dist. Pune 412210	Plot No 14, North: Colony Road, South: Plot No 22		Thousand only)		

The e-auction of the above mentioned property would be conducted through the e-auction Service provider Antares Systems ltd, #24, Sudha Complex, 4th Block, Basavesvasa Nagar, Bangalore Contact person: Mr. Viiav Kumar, S. & Mr. Manohar V. & Mr. G. K. Ramu, Mob.: 917207042074/9945266022/9665721619 for Maharashtra/ Pune Contact person, Mr. Sanjay K. Chandak, Mob.: 9665721619 E-mail ID: vijaykumar.s@antaressystems.com and sanjay.kc@antaressystems.com and sanjay.kc@etenderwizard.com. Toll Free No.: 1800 1026 185. Landline: 080-49352000 www.tenderwizard.com/ANB This is also a notice to the borrower(s)/guarantor(s)/mortgagor(s)/legal heirs of the above loan under Rule 8 (6) and Rule 9 of the Securitization and Reconstruction of Financial Assets and **Enforcement of Security Interest Act 2002** Authorised Officer, Wagholi Branch Place : Wagholi, Date : 11-02-2020

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2019

Standalone (Ind AS) Consolidated (Ind AS) **Particulars** Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended Year Ended Quarter Ended Year Ended Quarter Ended Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended 31-12-2019 30-09-2019 31-12-2018 31-12-2019 31-12-2018 31-03-2019 31-12-2019 30-09-2019 31-12-2018 31-12-2019 31-12-2018 31-03-2019 (Refer notes below) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) (Unudited) (Audited) (Unaudited) Revenue from operations 97,050.84 (a) Net sales 17,316.48 17,426.23 15,998.97 49,295.04 46,003.77 26,386.20 27,637.31 76,859.55 61,311.40 25,097.79 71,790.02 (b) Other operating income 846.37 471.96 321.39 1,753.93 1,172.11 1,737.27 969.41 513.09 452.66 1,875.25 1,229.92 1,603.84 Total revenue from operations 18,162.85 17,898.19 16,320.36 51,048.97 47,175.88 63,048.67 27,355.61 28,150.40 25,550.45 78,734.80 73,019.94 98,654.68 Other income 944.91 1,924.68 (846.41)3,555.00 3,072.25 4,756.14 329.63 808.25 (1,090.15)1,154.57 1,690.80 2,081.37 Total income (I + II) 19,107.76 19,822.87 15,473.95 54,603.97 50,248.13 67,804.81 27,685.24 28,958.65 24,460.30 79,889.37 74,710.74 1,00,736.05 IV Expenses 5,675.87 5,365.47 13,309.62 15.858.51 6.922.15 6,466.53 18,302.48 (a) Cost of materials consumed 6,153.78 17.023.38 7,318.05 19,474.73 24,447.12 (b) Purchase of stock-in-trade 928.73 908.24 2,536.10 3,111.41 2,788.10 8,486.51 8,044.79 9,762.98 921.42 2,816.28 3,012.95 2,914.14 (c) Changes in inventories of finished goods. work-in-progress and stock-in-trade (135.20)196.85 (24.78)(31.19)1,549.31 4.718.11 (770.18)606.86 (1,612.05)(735.35)(1.331.07)(586.68)5,572.46 2.641.23 3,457.94 2,320.86 8,299.33 9.699.80 6.866.00 17,305.36 15.614.85 20.560.70 (d) Employee benefits expense 7,457.54 5.030.81 595.74 (e) Finance costs 651.67 551.82 1,928.17 1,712.06 2,238.14 960.58 897.71 885.35 2,788.44 2,526.74 3,345.85 (f) Depreciation, amortisation and impairment expense 378.24 333.22 257.04 1,033.11 799.31 1,062.79 1,059.99 941.61 831.01 2,908.91 2,449.35 3,259.05 (g) Other expenses 4,446.15 3,833.52 4,257.02 11,913.98 11,736.01 16,484.52 8,119.02 6.918.83 7,552.70 21,879.60 20,172.20 28,612.56 22,920.01 Total expenses (IV) 15,001.36 13,635.67 42,983.06 53,074.82 24,975.43 89,401.58 15,077.80 39,099.95 25,485.64 72,108.20 65,779.34 Profit/(loss) before exceptional items and tax (III - IV) 11,334.47 4,106.40 4,745.07 1,838.28 11,620.91 11,148.18 14,729.99 2,709.81 3,473.01 1,540.29 7,781.17 8,931.40 Exceptional items (Refer note 5) (3,451.85)(3,451.85)(1,671.82)(1,671.82)Profit/(loss) before tax (V - VI) 4,106.40 4,745.07 1,838.28 11,620.91 14,600.03 18,181.84 2,709.81 3,473.01 1,540.29 7,781.17 10,603.22 13,006.29 VIII Tax expense: 3,834.95 4,765.42 Current tax 717.41 713.19 309.32 2,035.37 2,986.51 1,117.45 1,030.15 629.89 3,107.22 3,891.17 Deferred tax (288.04)(165.26)(468.07)(456.63)(536.14)(316.03)(112.56)(253.01)(921.26)(1,009.06)(66.27)(882.67) Profit/(loss) for the period from continuing 2,555.42 operations (VII - VIII) 3,455.26 4,319.92 1,694.22 10,053.61 12,070.15 14,883.03 1,908.39 1,163.41 5,556.62 7,633.31 9,249.93 Profit/(loss) before tax from discontinuing operations 398.25 2,028.34 2,028.34 Tax expense of discontinuing operations: Current tax 119.25 650.29 650.29 Deferred tax 14.51 39.96 39.96 Profit/(loss) for the period from discontinuing operations (X - XI) 264.49 1,338.09 1,338.09 Profit/(loss) for the period for continuing and discontinuing operations (IX + XII) 3,455.26 4,319.92 1,958.71 10,053.61 13,408.24 16,221.12 1,908.39 2,555.42 1,163.41 7,633.31 9,249.93 5,556.62 Other comprehensive income A (i) Items that will not be reclassified to profit or loss (17.06)(43.72)(17.61)(42.75)(40.96)(54.38)(21.01)(164.35)(16.69)-223.61 15.15 (259.39)(ii) Income tax relating to items that will not be reclassified to profit or loss 9.72 14.04 9.84 6.03 40.92 6.15 18.19 14.31 19.00 B (I) Items that will be reclassified to profit or loss 353.53 (947.49)566.06 (181.86)(2,759.19)(3,710.57)(ii) Income tax relating to items that will be reclassified to profit or loss (39.37)(81.50)(56.92)(95.88)70.75 (229.50)Total comprehensive income 3,447.92 4,290.24 1,947.25 10,029.05 13,381.59 16,185.74 2,211.38 1,391.94 1,661.89 5,096.19 4,967.04 5,096.27 Total comprehensive income attributable to: XVI Non-controlling interests 0.95 0.47 0.09 1.70 0.01 0.11 Owners of the Company 5,094.49 3,447.92 4,290.24 1,947.25 10,029.05 13,381.59 16,185.74 2,210.43 1,391.47 1,661.80 4,967.03 5,096.16 XVII Other equity 1,19,138.72 55,769.67 XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) 12.25 15.31 6.00 42.78 52.75 6.76 9.06 4.12 19.69 27.05 35.63 32.78 Diluted EPS (in Rupees) 12.25 52.74 27.05 32.78 15.31 6.00 35.63 42.78 6.76 9.06 4.12 19.69 XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) 0.94 4.74 4.74 Diluted EPS (in Rupees) 0.94 4.74 Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) 12.25 15.31 6.94 47.52 57.49 6.76 9.06 4.12 19.69 27.05 32.78 35.63 Diluted EPS (in Rupees) 12.25 15.31 6.94 47.52 9.06 27.05 32.78 35.63 57.49 6.76 4.12 19.69

Notes:

5 "Exceptional item:

1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5 July, 2016.

4 Pursuant to the Taxation Law (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20 September 2019 which is effective 1 April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and

- 2 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 14 February, 2020. 3 The results for the quarter and nine months ended 31 December, 2019 presented were subjected to a "Limited Review" by the statutory auditors of the Company who have issued an unmodified report on the said results.
- cess subject to certain conditions. The Company upon the amendment made an assessment of the Impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also remeasured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
- Exceptional items in the standalone (Ind AS) financial results for quarter and nine months ended 31 December, 2018 and for the year ended 31 March, 2019, primarily comprises net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS) for quarter and nine months ended 31 December, 2018 and for the year ended 31 March 2019 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles 6 "Effective 1 April, 2019, the Company has adopted Ind AS 116 "Leases" using the modified retrospective method. The Company has applied the standard to the lease contracts existing on 1 April 2019 with the cumulative impact recognised on the date of initial application. Accordingly, previous period information has not been restated. On initial application date, the Company has recognised a lease liability measured at the present value of the remaining lease payments, and right-of-use (ROU) asset at an amount equal to lease liability (adjusted for any related prepayments). Also, the Company has
- elected not to apply the requirements of Ind AS 116 to short-term leases and certain leases for which the underlying asset is of low value. Accordingly, on transition to Ind AS 116 to short-term leases and certain leases for which the underlying asset is of low value. Accordingly, on transition to Ind AS 116 to short-term leases and certain leases for which the underlying asset is of low value. current period, operating lease expenses which were recognised as other expenses in previous periods is now recognised as depreciation expense for the right-of-use asset and finance cost for imputed interest on lease liability. The adoption of this standard did not have any significant impact on the profit for the period and earnings per share." 7 The Board of Glenmark Pharmaceuticals Limited (the 'Company') at its meeting held on 21 January, 2020 approved the transaction to sell its gynaecology business in India and Nepal for Rs 1,150 million, subject to various transaction costs and other adjustments, to Integrace Private Limited.
- 8 The list of subsidiaries as of 31 December, 2019 is provided in Annexure A. 9 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical business level, comprising a generic business l
- Pharmaceuticals. 10 As at 31 December, 2019, pursuant to Employee Stock Options Scheme 2016, 445,913 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

11 The Company was publishing consolidated financial results as per International Financial Reporting Standards Board, as permitted by SEBI circular CIR/CFD/DIL/1/2010 dated 5 April 2010 and also under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on a voluntary basis. The Company has decided to discontinue the aforementioned with effect from 1 April 2019.

12 Diluted EPS has been computed considering the effect of conversion of ESOPs.

13 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited Annexure A

List of entities included in the consolidated financial results for the guarter and nine months ended 31 December 2019

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals SA (Formerly known as Glenmark Pharmace Pharmaceuticals S.R.L. 8. Glenmark Pharmaceuticals Inc. 11. Glenmark Pharm Pharmaceuticals Colombia SAS, Colombia 16. Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Pharm B.V. 30.Glenmark Arzneimittel Gmbh 31.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Canada Inc. 32.Glenmark Pharmaceuticals Canada Inc. 34.Viso Farmaceuticals Canada Inc. 35.Glenmark Pharmaceuticals Canada Inc. 36.Glenmark Pharmaceuticals Canada Inc. 36.Glenmark Pharmaceuticals Canada Inc. 37.Glenmark Phar Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Pharmaceuticals Singapore Pte. Ltd. 41. Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43. Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

> For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

Mumbai, February 14, 2020

financialexp.epan.in





थकबाकीदार दूरसंचार कंपन्यांना उद्यापर्यंत मुदत

थिकत महसूल अदा न केल्यास सर्वोच्च न्यायालयाच्या आदेशानुसार कारवाई

ज्या दूरसंचार कंपन्यांनी विनियोजित ज्या दूरसचार कंपन्याना विानगाजत एकूण महसुलाची थक बाकी वेळेत अदा केली नाहीं, त्यांच्यावर सर्वोच्च न्यायालयाच्या आदेशानुसार कारवाई करण्यात येईल असे दूरसंचार खात्यान म्हटले होते. शनिवारी अनेक कार्यालयांना सुटी असल्याने दूरसंचार खात्याने या कंपन्यांना थकबाकी अदा करण्यास सोमवारी सायंकाळपर्यंत

करण्यास सोमवार्ष सार्वकाळपर्यंत मुदत दिव्ही असून त्यानंतर कारवाई केली जाणार आहे. वा कंपन्यांना दंडवसूली व कारवाईबाबत परवाना निकपांच्या आधारे नव्याने नोटीसा जारी करण्यात येणार आहेत. दूरसंचार खात्याने थकबाकी असलेल्या कंपन्यांना आतापर्यंत पाच नोटिसा पाठवल्या आतापवत पाच नाटिसा पाठवरत्या असून त्यात स्मरणपत्रांचाही समावेश आहे. ३१ ऑक्टोबर, १२ नोव्हेंबर, २ डिसेंबर, २० जानेवारी व १४ फेब्रुवारी या तारखांना या नोटिसा जारी करण्यात आल्या होत्या. सर्वोच्च करण्यात आल्या हात्या. सवाच्य न्यायालयाच्या आदेशानुसार या कंपन्यांनी विनियोजित एकूण महसुलाची थकबाकी अदा करणे अपेक्षित होते. या कंपन्यांना त्यासाठी दूरसंचार खात्याने कधीच मुदतवाढ



असले तरी आता प्रत्येक विलंबानसार असल तर्रा आता प्रत्यका विख्वानुसार त्यांच्यावर अत्याई केली जाणार आहे. दूरसंचार खात्याने दूरसंचार कंपन्यांना शुक्रवारी मध्यराजी खरमरीत आदेश जारी केला. सर्वोच्च न्यायाल्याने थकावाकी वस्तुलीबाबत त्यांचे आदेश पाळले जात नसल्याबाबत तीच्च संताय व्यक्त केला होता. न्यायालयाने या कंपन्यांवर कृतली. न्यायालयान या कपन्यापर कुठलीही कठोर कारवाई करण्याचा आदेश टाळला होता तरी या कंपन्यांनी १४ फेब्रुवारीला थकबाकी अदा केली नाही. ही बाब न्यायप्रविष्ट असल्याने गुंतागुंत टाळण्यासाठी आम्ही अंतर्गत प्रक्रियेनुसार वसुलीचे आदेश जारी केले आहेत, असे दूरसंचार खात्याच्या सूत्रांनी शनिवारी स्पष्ट केले.

स्पष्ट कल. आतापर्यंतच्या अंदाजानुसार एकूण १.४७ लाख कोटींच्या विनियोजित

एकूण महसुलाची थकबाकी या कंपन्यांकडे आहे. सार्वजनिक कंपन्यांची (दूरसंचार सेवा न देणाऱ्या) थकबाकी २.६५ लाख रेणाऱ्या) ध्रक्तवाकी २.६५ लाख कोटीची अस्तू लात 'मेल' चा वाटा २.६५ लाख कोटीची अस्तू नाता 'मेल' चा वाटा २.६५ लाख कोटीची आहे. है प्रगण एकुण रुक्तभे का स्थान प्रश्ति का स्थान प्राथम प्रवास वार्यावालयात जाण्याचा अधिकार आहे. एअटलेल्ल २० फ कुबारिअस्ट १० लाग कोटी भरण्यास सांगण्यात आले असून उर्वीरत सक्रम १७ मार्चपूर्वी भरावी असे कटले आहे. एअटलेल्लक इंपकृण ३५५८६ कोटीची थकवाकी आहे. त्यात परवाना शुल्क वा तरंगलाधी वार्ष्ट्रक वा तरंगलाधील एक्ल चावा सामार्थ्य तरंगलहरी वापर शुल्क यांचा समावेश तरगल्हरा वापर शुल्क वाचा समावश आहे. व्होडाफोन-आयडिया यांनी शनिवारी सांगितले की, किती रक्कम भरणे शक्य आहे याचा आदावा आमहीचेत आहोत. त्यांची थकवाकी ५३०३८ कोटी रुपये आहे त्यात २४७९९ कोटी तरंगल्हरी शुल्क तर २४७२९ कोटी तरगल्हरा शुल्क तर २८३०९ कोटी परवाना शुल्क तर भारतात एकूण २२ दूरसंचार पश्चित्र असून त्यात उत्तर प्रदेश पश्चित्रास शुक्रवारी शुल्क भरण्यास सांगण्यात आले होते. राजस्थान पश्चित्रासही नोटीस देण्यात आली आहे.

'...तर व्होडाफोन-आयडिया व्यवसायातून बाहेर'

वत्तसंस्था, नवी दिल्ली

कर्जबाजारी असलेल्या को डाफोन क्रजबाजारा असल्ल्या काडाकान आयडिया दूरसंचार कंपनीने त्यांच्या एकूण विनियोजित महसुली थकबाकीचा शनिवारी अंदाज घेतला असून ती अदा करण्याचे मान्य केले असले. तरी या घतला असून तो अदो करण्याच मान्य केले असले, तरी या व्यवसायात राष्ट्रण्याबावत त्यांनी चिंता व्यक्त केली आहे. कंपनीने सांगितले,की सर्वोच्च न्यायालयाच्या आदेशानुसार विनियोजित महसुलाची रक्कम अदा करण्याचा

विचार आम्ही करीत आहोत. विचार आमहा करात आहात कंपनीने एकूण परिस्थितीचा आढावा पेताला आहे, कारण २४ ऑक्टोबर २०१९ रोजी सर्वोच्च न्यायालयाने थकबाकी अदा करण्याचा आदेश दिला होता. जेवढी थकबाकी आहे ती भरण्याचा प्रयत्न येत्या काही ता भरण्याचा प्रयत्न वत्या काहा दिवसात केला जाईल. व्होडाफोन आवडिया लि. कंपनीची एकूण थकबाकी ५३ हजार ३८ कोटी रुपये असून त्यात २४ हजार ७२९ कोटी हे तरंगलहरी शुल्क तर २८ हजार ३०९ कोटी हे परवाना शुल्क आहे.

व्यवसायातून बाहेर पडण्याचा इशारा कंपनीने दिला आहे. कंपनीच्या ३१ कपनान दिला आहे. कपनाच्या ३२ डिसेंबर २०१९ अखेरच्या आर्थिक विवरण पत्रात म्हटले आहे,की आम्ही या व्यवसायात राहू की नाही याचीच चिंता वाटत असन न्यायालयाच्या पूरक आदेशात दिलाशाची मागणी आम्ही एका ादलाशाचा मागणा आस्हा एका अर्जातून केली होती त्यावर काय निर्णय होतो यावर ठरवू . याबाबत पुढील सुनावणी १७ मार्चला होणार आहे.

थकबाकीत दिलासा न दिल्यास या

बँकांना मोठी जोखीम - स्टेट बँक अध्यक्षांचे भाकीत

सारेच भरडले जाणे

नवी दिल्ली : कोणत्याही दूरसंचार कंपनीने दिवाळखोरी घोषित केल्यास, त्याची बँकांना मोठी किमत मोजावी लागेल, असे स्टेट बँकेवे अध्यक्ष रजनीश कुमार यांनी शनिवारी स्पष्ट केले. त्यांनी हे विधान केले. या

आयडिया यांसह अन्य कंप्रन्यांकडून गतकाळातील एकूण १.४७ लाख कोटी रुपयांच्या थकबाकीच्या ताबडतोब वसलीच्या शुक्रवारी दिलेल्या, भारती कंपन्यांकडून कसे केले एअरटेल, व्होडाफोन- जाते, या संबंधाने 'थांबा आणि पाहा' असेच तूर्त आपले धोरण असल्याचे त्यांनी सांगितले. तथापि कोणत्याही उद्योगावरील नकरात्मक प्रभावाचे व्यापक परिणाम हे मोठ्या परिसंस्थेवर होत असतात, मग त्यात बँका असोत, कर्मचारी असोत, विक्रेते वा ग्राहक असोत

अपरिहार्य दिसते, अशा शब्दात त्यांनी इशारा दिला. रिझदर्ड बँकेचे गट्निर शक्तिकांत दास यांनीही या प्रकरणी बैंकांवरील परिणामांबाब्ह स्पष्ट वक्तव्य केले नसले, तरी मध्यवर्ती बँकेकडून यासंबंधाने अंतर्गत चर्चाविमर्श सुरू असल्याचे स्पष्ट केले.

सरकारकडून 'वित्तीय विवेका'चे उचित पालन - गव्हर्नर दास

अर्थसंकल्पातील तरतुदींनी महागाईला बळ मिळण्याची शक्यताही फेटाळली

देशभरात बँकांच्या पतपरवठ्यात देशभरात बैंकांच्या पतपुरक्यात आशादगी वाह दिस्तून येव अस्त्र, अलीकडेच मोडल्या गेलेल्या अर्थसंकरणातील तरातुर्दीमधून कालनाबाडीला कव्य दिले जाणधूनी शक्यताही रिझर्क बैंकचे गव्हर्नर शक्तिकांत दास योनी फेटाळून लावली. सरकारकड्ड "विना विवेकं पाळकरंग सरकारकड्ड" अस्त्री

विवक पाळला जात आह, अशा प्रशस्तीची पावतीही त्यांनी दिली. संसदेत अर्थसंकल्प मांडला गेल्यानंतर, आयोजित रिझर्व्ह बूँकेच्या संचालक मंडळाच्या पहिल्या बैठकीत सचालक मंडळच्या पाहल्या बठकात द्यस यांनी आजवर केली गेळेल व्याजदर कपात ही सामान्य कर्जदारांपर्यंत पोहचविल्ली जाईल, असा विशासही व्यक्त केला. या बैठकीत अर्थमंत्री निर्मेला सीतारामन यांनी अर्थसंकल्पातील विविध यांनी अर्थसंकल्पाताल तरतुर्दीचा उहापोह केला. कोणत्याही अर्थ

तरतुर्वेचा उद्यापीह केला. कोणत्याही अर्थसंकल्पाचा चलनवादीला कारक उरणारा प्रमुख घटक हा वित्तीय तुर्वेची आंकडेवारी हाच असतो. कारण अशा स्थितीत सरकारची उसनवारी प्रचंड वाढते. तथापि विद्यमान सरकारकडून वित्तीय

विवेक तत्त्वाचे काटेकोर पालन केले विवक तत्वाचे काटकर एाठन कर जात अबहे, असे दास यांनी कौतुकोदगार काढले. वित्तीय जवाबदारी आणि अधंसंकल्पीय व्यवस्थापन (एफआरबीएम) कारवातील 'पळ्वार' असणारे कल्प वाररून विद्यामान तसेच आमार्ग आर्थिक व्यत्तिवित्त वृटीचे उदिष्ट वाढविले गेले असले तरी ते उद्दिष्ट बाढावर गरु असल तरा त एफआरबीएम समितीच्या आतील आहे, अशी पुस्तीही त्यांनी जोडली. अभेक्षेपेश्वा कमी कर महसूल गोळा झाल्याने, सरकारने २०१९-२० सालासाठी वित्तीय तुटीचे उदिष्ट सकल राष्ट्रीय उत्पादनाच्या तलनेत सकल राष्ट्राय उत्पादनाच्या तुलनत ३.३ टक्के या पूर्वनिर्णीत्त पातळीवरून ३.८ टक्क्यांवर नेले आहे. अल्पबचत योजनांत गुंतलेल्या निधीतून सरकारच्या उसनवारीतील मोठा हिस्सा वेणार असल्याने, त्याचा चलनवाढीत भर घालणारा परिणाम दिसून येणार नाही, असा निर्वाळा दास ादसून वर्णार नाहा, असा निवाळी दोस यांनी दिला. अर्थात महागाई निर्देशांकाने ७.५९ टक्के म्हणजे, रिझर्व्ह बैंकेच्या दृष्टीने सुसल्य पातळीला जानेवारी महिन्यात पार केले असल्याचे दिसून येत आहे.

\mathbf{e} glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenm

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2019

Standalone (Ind AS) Consolidated (Ind AS) 31-12-201 (Unaudite 31-12-2019 (Refer notes below) Revenue from operations
(a) Net sales
(b) Other operating incor
Total revenue from operat
Other income 17,316.48 17,426.23 471.96 17,898.19 1,924.68 19,822.87 49,295.04 15,998.97 26,386.20 27,637.31 25,097.79 969.41 27,355.61 329.63 27,685.24 513.09 28,150.40 808.25 28,958.65 78,734.80 1,154.57 79,889.37 2,081.37 6,466.53 7,318.05 2,914.14 1,549.31 7,457.54 1,712.06 799.31 11,736.01 39,099.95 11,148.18 (3,451.85) 14,600.03 (1,331.07) 15,614.85 2,526.74 2,449.35 20,172.20 65,779.34 8,931.40 (1,671.82) 10,603.22 Exceptional items (Refer notes)
Profit (loss) before lax (V · V)

Current tax

Current tax

Profit (loss) for the period from continuing
Profit (loss) for the period from continuing
Profit (loss) for the period from continuing operations?

Tax expense of discontinuing operations:

Current tax

Deferred tax

or the period from discontinuing operations (V · V)

Profit (loss) for the period from discontinuing operations (V · X · V)

Profit (loss) for the period from discontinuing operations (V · X · V)

Profit (loss) for the period for on discontinuing operations (V · X · V)

A (i) Items that will not be reclassified to profit or loss

(ii) Income tax realising to letners that will not be reclassified to profit or loss

10 Items that will be reclassified to profit or loss
reclassified to profit or loss

Total comprehensive income

To 4,106.40 4,745.07 1,838.28 11,620.91 2,709.81 3,473.01 1,540.29 7,781.17 4,765.42 (1,009.06) 717.41 (66.27) 2,035.37 (468.07) 2,986.51 (456.63) 1,117.45 (316.03) 309.32 (165.26) 3,834.95 (536.14) 1,030.15 (112.56) 629.89 (253.01) 3,891.17 (921.26) 4,319.92 3,455.26 1,694.22 10,053.61 12,070.15 14,883.03 1,908.39 2,555.42 1,163.41 5,556.62 7,633.31 9,249.93 119.25 650.29 264.49 1,338.09 1,338.09 3 455 26 4 319 92 1.958.71 10.053.61 13 408 24 16,221,12 1 908 39 2 555 42 1 163 41 5 556 62 7 633 31 9 249 93 (17.06) (43.72) (17.61) (42.75) (40.96) (54.38) (21.01) (164.35) (16.69) -223.61 15.15 (259.39) 45.80 (3,710.57) 9.72 14.04 6.15 18.19 14.31 19.00 29.86 (947.49) 9.84 353.53 40.92 (181.86) (95.88) 5,096.19 (81.50) 1,391.94 (56.92) 1,661.89 70.75 4,967.04 (229.50) 4.290.24 3,447.92 1.947.25 10.029.05 0.95 1,391.47 0.09 1.70 5,094.49 0.01 4,967.03 3,447.92 4.290.24 1.947.25 10.029.05 13.381.59 16,185.74 1,19,138.72 32.78 15.31 6.00 35.63 35.63 42.78 4.12 27.05 0.94 4.74 4.74

own year, on't by but again of this plan scale of the plan of the

Turk A.

Tentiles included in the consolidated financial results for the quarter and nine months ended 31 December 2019

mark Pharmaceuticals (Europp R80 Ltd, U.K. 2.Glemnark Pharmaceuticals S.P.O. 9.Glemnark Pharmaceuticals No. 9.G. P.C. 9.Glemnark Pharmaceuticals S.P.O. 9.Glemnark Pharmaceuticals No. 9.G. P.C. 9.Glemnark Pharmaceuticals S.P.O. 9.Glemnark Pharmaceuticals No. 9.G. 9.Glemnark Pharmaceuticals S.P.O. 9.Glemnark Pharmaceuticals No. 9.G. 9.Glemnark Pharmaceuticals S.P.O. 9.Glemnark Pharmaceuticals S

Glenn Saldanha Chairman & Managing Director